Patent · US Active

Polymorph form of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid

US9187463B2 · kind B2 · utility

0Cited by

1References

10Claims

0Family size

Assignee

RaQualia Pharma Inc. · US

Inventors

Toyoharu Numata · Ebeye, US
Hirohide Noguchi · Ebeye, US
Nobuaki Waizumi · Osaka, JP
Takashi Kojima · Tokyo, JP

Key dates

Filing date	May 18, 2012
Grant date	Nov 17, 2015
Priority date	—
Expiry date	May 18, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel crystal forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2H-pyran-4-carboxylic acid. More particularly, the invention relates to polymorph forms (Polymorph Form I or Polymorph Form II), and to processes for the preparation of, compositions containing and to uses of, such polymorph forms.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.